Skip to main content
. Author manuscript; available in PMC: 2021 Sep 8.
Published in final edited form as: Vaccine. 2017 Feb 16;36(22):3090–3100. doi: 10.1016/j.vaccine.2017.01.068

Figure 7. IgG ELISA antibody titers (EC50) against recombinant EBOV GP and VP40 after live virus challenge in the passive protection experiment.

Figure 7.

Serum samples of all surviving animals in selected groups were collected at the end of the study and after irradiation analyzed for IgG titers against EBOV GP and VP40 (individually).

Panel A: Antibody titers to GP antigen. Panel B: Antibody titers to VP40 antigen.